Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1 peptide vaccine in metastatic melanoma
NCT00020397Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2000
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NY-ESO-1b peptide vaccine in melanoma (3 arms), sponsored by National Cancer Institute. Primary endpoints: Immunologic response, Toxicity and 1 more. Started Nov 2000; status: completed.
02
Drugs
NY-ESO-1b peptide vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00020397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020397.